COM.TO - Cardiome Pharma Corp.

Toronto - Toronto Delayed Price. Currency in CAD
2.92
0.00 (0.00%)
At close: 3:58PM EDT
Stock chart is not supported by your current browser
Previous Close2.92
Open2.91
Bid2.91 x 0
Ask3.00 x 0
Day's Range2.91 - 3.04
52 Week Range1.64 - 6.06
Volume10,700
Avg. Volume23,429
Market Cap101.817M
Beta-2.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Zacks Small Cap Research15 days ago

    CRME: Cipher to Get Canadian Assets

    Cardiome Pharma Corp. (CRME) issued a press release reporting 2017 full-year results on March 13, 2018, and filed its 2017 financial statements and management discussion & analysis on SEDAR three weeks later. During 2017, Cardiome advanced Xydalba in Europe with a commercial launch in several EU states.

  • Benzingalast month

    Canaccord: Cardiome Pharma's Sale Of Canadian Business 'A Highly Positive Catalyst' For Shares

    CARDIOME PHARMA CORP (NASDAQ: CRME ) announced Tuesday it has agreed to divest its Canadian business to Cipher Pharmaceuticals for the U.S. dollar equivalent of $19.7 million.  The Analyst Canaccord Genuity's ...

  • Zacks Small Cap Researchlast month

    CRME: Cardiome’s 2017 Full Year Results

    Cardiome was involved in substantial activity during the prior twelve months, beginning with the recognition of sales for Zevtera/Mabelio, the launch of Xydalba in several new geographies, and the expansion of the reach of Brinavess.  China’s regulatory authority granted Aggrastat an additional indication and SteadyMed is on track for its new drug application (NDA) for Trevyent.  As we began 2018, Esmocard posted record months in both January and February. In September, Cardiome entered into an agreement with Basilea to commercialize ceftobiprole (Zevtera/Mabelio) in 34 European countries and Israel.  Following the transaction, revenues were recognized on Cardiome’s income statement and beginning January 1st, 2018 all of Basilea’s sales representatives were added to Cardiome’s sales force.  Management commentary noted that they were able to achieve historical peak sales levels of the drug in January and surpass that in February, suggesting that better days are still ahead.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of COM.TO earnings conference call or presentation 13-Mar-18 8:30pm GMT

    Q4 2017 Cardiome Pharma Corp Earnings Call

  • Associated Presslast month

    Cardiome reports 4Q loss

    The Vancouver, British Columbia-based company said it had a loss of 24 cents per share. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Cardiome Pharma Corp (TSE:COM): Is Breakeven Near?
    Simply Wall St.2 months ago

    Cardiome Pharma Corp (TSE:COM): Is Breakeven Near?

    Cardiome Pharma Corp’s (TSX:COM): Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company’sRead More...

  • Are Cardiome Pharma Corp’s (TSE:COM) Interest Costs Too High?
    Simply Wall St.2 months ago

    Are Cardiome Pharma Corp’s (TSE:COM) Interest Costs Too High?

    Investors are always looking for growth in small-cap stocks like Cardiome Pharma Corp (TSX:COM), with a market cap of CA$63.04M. However, an important fact which most ignore is: how financiallyRead More...

  • Best TSX Growth Stocks
    Simply Wall St.2 months ago

    Best TSX Growth Stocks

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...

  • Zacks Small Cap Research3 months ago

    CRME: Initiating Coverage

    Through its acquisition of Correvio in late 2013, Cardiome procured a salesforce, EU licenses and worldwide sales rights (ex-US) for Aggrastat.  This action provided immediate sales and infrastructure to commercialize the internally developed Brinavess as well as the structure necessary to layer on additional products.  Following this initial transaction, Cardiome has obtained the rights to four other products, including two complementary anti-infectives. Based on our forecasts which include revenues for currently licensed drugs and a probability-weighted contribution from Trevyent, we expect breakeven on an operational basis in 2020.  This forecast assumes growth in all products, with a greater contribution from Xydalba and Zevtera in 2018 and initial contribution from Trevyent in 2020.

  • With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp (TSX:COM) Underperform Its Industry?
    Simply Wall St.4 months ago

    With 13.4% Earnings Drop Lately, Did Cardiome Pharma Corp (TSX:COM) Underperform Its Industry?

    After looking at Cardiome Pharma Corp’s (TSX:COM) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assessRead More...

  • Top Growth Stocks To Buy
    Simply Wall St.5 months ago

    Top Growth Stocks To Buy

    Investors seeking to increase their exposure to growth should consider companies such as Equity Financial Holdings and SEMAFO. Analysts are generally optimistic about the future of these stocks, based onRead More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of COM.TO earnings conference call or presentation 14-Nov-17 9:30pm GMT

    Q3 2017 Cardiome Pharma Corp Earnings Call

  • Cardiome Pharma Corp. :COM-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 20, 2017
    Capital Cube5 months ago

    Cardiome Pharma Corp. :COM-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 20, 2017

    Categories: Yahoo FinanceGet free summary analysis Cardiome Pharma Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Cardiome Pharma Corp. – Aeterna Zentaris Inc. and Acasti Pharma Inc. Class A (AEZS-CA and ACST-CA) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more (Read more...)

  • Associated Press5 months ago

    Cardiome reports 3Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 20 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by ...

  • What’s Installed For Cardiome Pharma Corp (TSX:COM)?
    Simply Wall St.6 months ago

    What’s Installed For Cardiome Pharma Corp (TSX:COM)?

    Cardiome Pharma Corp (TSX:COM), a CADCA$70.60M small-cap, operates in the healthcare industry, which faces key trends such as rising demand fuelled by an aging population and the growing prevalence ofRead More...

  • Cardiome Pharma Corp (TSX:COM): Time For A Financial Health Check
    Simply Wall St.6 months ago

    Cardiome Pharma Corp (TSX:COM): Time For A Financial Health Check

    Investors are always looking for growth in small-cap stocks like Cardiome Pharma Corp (TSX:COM), with a market cap of USD $76.81M. However, an important fact which most ignore is: howRead More...

  • What Falling Estimates & Price Mean for Cardiome (CRME)
    Zacks8 months ago

    What Falling Estimates & Price Mean for Cardiome (CRME)

    Cardiome (CRME) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.

  • Cardiome Pharma Corp. :COM-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017
    Capital Cube8 months ago

    Cardiome Pharma Corp. :COM-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017

    Categories: Yahoo FinanceGet free summary analysis Cardiome Pharma Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Cardiome Pharma Corp. – Aeterna Zentaris Inc. and Medicure Inc. (AEZS-CA and MPH-CA) that have also reported for this period. Highlights Summary numbers: Revenues of CAD 7.74 million, ... Read more (Read more...)

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of COM.TO earnings conference call or presentation 8-Aug-17 8:30pm GMT

    Q2 2017 Cardiome Pharma Corp Earnings Call

  • Associated Press8 months ago

    Cardiome reports 2Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of 26 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by ...

  • Thomson Reuters StreetEvents11 months ago

    Edited Transcript of COM.TO earnings conference call or presentation 15-May-17 8:30pm GMT

    Q1 2017 Cardiome Pharma Corp Earnings Call

  • Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher
    Zacks11 months ago

    Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher

    Cardiome Pharma Corp. (CRME) shares rose a little above 6% in the last trading session.

  • Associated Press11 months ago

    Cardiome reports 1Q loss

    The Vancouver, British Columbia-based company said it had a loss of 20 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...